Title: Bridging Communities in the field of Nanomedicine
Authors: HALAMODA KENZAOUI BLANKABACONNIER SIMONBASTOGNE THIERRYBAZILE DIDIERBOISSEAU PATRICKBORCHARD GERRITBORGOS SVEN EVENCALZOLAI LUIGICEDERBRANT KARINDI FELICE GABRIELLADI FRANCESCO TIZIANADOBROSVOLSKAIA MARINAGASPAR ROGERIOGRACIA BELENHACLEY VINCENTLEYENS LADALIPTROTT NEILLMARGRIET PARKPATRI ANILROEBBEN GERTROESSLEIN MATTHIASTHUERMER RENEURBAN LOPEZ PATRICIAZUANG VALERIEBREMER SUSANNE
Citation: REGULATORY TOXICOLOGY AND PHARMACOLOGY vol. 106 p. 187-196
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE
Publication Year: 2019
JRC N°: JRC113641
ISSN: 0273-2300 (online)
URI: https://publications.jrc.ec.europa.eu/repository/handle/JRC113641
DOI: 10.1016/j.yrtph.2019.04.011
Type: Articles in periodicals and books
Abstract: An early dialogue between nanomedicine developers and regulatory authorities are of utmost importance to anticipate quality and safety requirements for these innovative health products. In order to stimulate interactions between the various communities involved in a translation of nanomedicines to clinical applications, the European Commission's Joint Research Centre hosted a workshop titled "Bridging communities in the Field of Nanomedicine" in Ispra/Italy on the 27th -28th September 2017. Experts from regulatory bodies, research institutions and industry came together to discuss the next generation of nanomedicines and their needs to obtain regulatory approval. The workshop participants came up with recommendations highlighting methodological gaps that should be addressed in ongoing Horizon 2020 projects addressing the regulatory science of nanomedicines. In addition, individual opinions of experts relevant to progress of the regulatory science in the field of nanomedicine were summarized in the format of a survey.
JRC Directorate:Health, Consumers and Reference Materials

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.